Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Uroplasty's SUI (stress urinary incontinence) product nears the US:

This article was originally published in Clinica

Executive Summary

The US FDA has issued Uroplasty with an approvable letter for its Macroplastique implants for treating female stress urinary incontinence (SUI), subject to the agency completing its auditing of the firm's manufacturing facilities, methods and controls. Since its introduction in Europe, over 60,000 people have been treated with Macroplastique, which is a soft tissue, injectable bulking agent for use in a minimally-invasive, out-patient procedure. In the US, SUI affects around 13 million people, 85% of whom are women, said the Minnetonka, Minnesota company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel